Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2021

View Archived Issues

Clonal fitness study may steer future cancer therapy

WNK2 is differentially expressed in MYD88-mutated Waldenstrom macroglobulinemia

Beijing Tide Pharmaceutical discloses new ATR kinase inhibitors

Fochon Pharmaceuticals patents PI3K inhibitors

Guangzhou Fermion Technology identifies new SST4 receptor agonists

Shanghai Longwood Biopharmaceuticals synthesizes PD-1/PD-L1 interaction inhibitors

Nanjing Legend Biotechnology describes new simian ICP47-based therapeutic cells

PRGN-3007 shows promise for treating mantle-cell lymphoma

Sleep-seizure EEG associations in TgBDNF mouse model of epilepsy

Liver humanized NSG-PiZ mouse model developed to test HBV antiviral therapies

Targeting CXCL16 shows therapeutic effects in model of TNBC

3SBio's Sunshine Guojian subsidiary to develop Numab's NM-28 in Greater China area

CVL-218 shows promising potency and safety in preclinical models

Ichnos grants Almirall global rights to develop and commercialize ISB-880 for autoimmune diseases

TYME-19 demonstrates antiviral effect against SARS-CoV-2 in human lung epithelial cells

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...